60 Degrees Pharmaceuticals, Inc. Files S-1 Registration Statement

TL;DR

<b>60 Degrees Pharmaceuticals, Inc. has filed an S-1 registration statement, indicating plans for a public offering of securities.</b>

AI Summary

60 DEGREES PHARMACEUTICALS, INC. (SXTPW) filed a IPO Registration (S-1) with the SEC on January 22, 2024. 60 Degrees Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on January 22, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. The filing is for a registration statement under the Securities Act of 1933. The company's business address is 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036. Geoffrey S. Dow is listed as President and Chief Executive Officer.

Why It Matters

For investors and stakeholders tracking 60 DEGREES PHARMACEUTICALS, INC., this filing contains several important signals. This S-1 filing is a prerequisite for a company to offer its securities to the public, signaling potential future fundraising or stock market entry for 60 Degrees Pharmaceuticals. The filing provides detailed information about the company's business, financial condition, and management, which is crucial for potential investors to assess the risks and opportunities associated with the company.

Risk Assessment

Risk Level: low — 60 DEGREES PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is an S-1 registration statement, which is a preliminary step for a public offering and does not contain specific financial performance data or operational details that would indicate immediate risk.

Analyst Insight

Monitor future filings for the prospectus and details regarding the proposed public offering, including the number of shares and pricing.

Key Numbers

• S-1 — Form Type (Registration Statement)
• 2024-01-22 — Filing Date (Date of SEC filing)
• 333-276641 — SEC File Number (Registration number)
• 1231 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — Filer name
• S-1 (regulator) — Form type
• 2024-01-22 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 2834 (industry) — Standard Industrial Classification Code
• 452406880 (identifier) — IRS Number
• 1025 CONNECTICUT AVENUE NW SUITE 1000 WASHINGTON DC 20036 (address) — Business address
• Geoffrey S. Dow (person) — President and Chief Executive Officer

Forward-Looking Statements

• 60 Degrees Pharmaceuticals, Inc. will successfully complete its public offering. (60 DEGREES PHARMACEUTICALS, INC.) — medium confidence, target: 2024-12-31
• The company's stock will experience volatility upon its public debut. (60 DEGREES PHARMACEUTICALS, INC.) — high confidence, target: 2024-06-30

FAQ

Industry Context

The company operates in the Pharmaceutical Preparations industry (SIC code 2834).

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed business descriptions and risk factors.
2. Track subsequent SEC filings for the prospectus and offering details.
3. Analyze the company's business model and market strategy once more information is available.

Key Dates

• 2024-01-22: Filing of S-1 Registration Statement — Initiates the process for a potential public offering of securities.

Year-Over-Year Comparison

This is the initial S-1 filing, so there is no prior filing to compare against for valuation or performance metrics.

Key Financial Figures

• $0.0001 — sting of one share of our common stock, $0.0001 par value per share, and one warrant ("
• $0.6260 — at an assumed public offering price of $0.6260 per Unit, based upon the last reported
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
• $383,755 — tlets was 1,633 boxes (a gross value of $383,755 at a WAC price of $235 per box), a subs
• $235 — oss value of $383,755 at a WAC price of $235 per box), a substantial increase from t
• $1,350 — one and azithromycin, which costs about $1,350 out of pocket. A treatment course of Ta
• $300 — prophylactic dose in dogs might cost < $300, offering a compelling alternative to s

Filing Documents

• ea191855-s1_60degrees.htm (S-1) — 4231KB
• ea191855ex1-1_60degree.htm (EX-1.1) — 188KB
• ea191855ex4-1_60degree.htm (EX-4.1) — 144KB
• ea191855ex4-2_60degree.htm (EX-4.2) — 99KB
• ea191855ex4-3_60degree.htm (EX-4.3) — 96KB
• ea191855ex4-4_60degree.htm (EX-4.4) — 126KB
• ea191855ex5-1_60degree.htm (EX-5.1) — 18KB
• ea191855ex23-1_60degree.htm (EX-23.1) — 2KB
• ea191855ex-fee_60degree.htm (EX-FILING FEES) — 27KB
• image_001.jpg (GRAPHIC) — 12KB
• image_002.jpg (GRAPHIC) — 43KB
• image_003.jpg (GRAPHIC) — 123KB
• ex5-1_001.jpg (GRAPHIC) — 23KB
• 0001213900-24-005285.txt (&nbsp;) — 15190KB
• sxtp-20230930.xsd (EX-101.SCH) — 96KB
• sxtp-20230930_cal.xml (EX-101.CAL) — 65KB
• sxtp-20230930_def.xml (EX-101.DEF) — 505KB
• sxtp-20230930_lab.xml (EX-101.LAB) — 848KB
• sxtp-20230930_pre.xml (EX-101.PRE) — 524KB
• ea191855-s1_60degrees_htm.xml (XML) — 1839KB

BUSINESS

BUSINESS 76 MANAGEMENT 109 EXECUTIVE COMPENSATION 114 PRINCIPAL STOCKHOLDERS 119 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 121 DESCRIPTION OF SECURITIES 121

UNDERWRITING

UNDERWRITING 128 EXPERTS 131 LEGAL MATTERS 131 WHERE YOU CAN FIND MORE INFORMATION 131 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the underwriter, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the underwriter take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction. i ABOUT THIS PROSPECTUS Throughout this prospectus, unless otherwise designated or the context suggests otherwise, all references to the "Company," "60P," the "registrant," "we," "our," or "us" mean 60 Degrees Pharmaceuticals, Inc., a Delaware corporation, and majority owned subsidiary 60P Australia Pty Ltd, an Australian proprietary company limited by shares; "year" or "fiscal year" means the year ending December

View Full Filing

View this S-1 filing on SEC EDGAR